Bladder Cancer

As new genetic and AI-powered tools emerge for bladder cancer screening, are we getting closer to reducing the need for invasive cystoscopies? In part five of the 2025 BackTable NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam engages in an insightful discussion with Dr. Sarah Psutka from the University of Washington and Dr. Katie Murray from NYU about the complexities and potential benefits of using biomarkers in non-muscle invasive bladder cancer (NMIBC).

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who’s on point for planning, administering, and optimizing combination therapies? Is it still the urologist, or does medical oncology play a more significant role now than it did before? In this episode of the BackTable 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt sits down with Dr. Tyler Stewart, medical oncologist from the University of California San Diego, to discuss the contemporary role of medical and surgical oncology in treating non-muscle invasive bladder cancer.

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology.

When a patient is diagnosed with non-muscle invasive bladder cancer (NMIBC), how do you tailor the conversation and treatment plan to their individual needs (and fears)? In part two of the 2025 NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam is joined by Dr. Sima Porten from UCSF and Dr. Patrick Hensley from the University of Kentucky to discuss patient-centered diagnostic and therapeutic approaches for non-muscle invasive bladder cancer.

How are leading urologic oncologists using advanced biomarkers and artificial intelligence to refine the diagnosis and management of non-muscle invasive bladder cancer (NMIBC)? In the opening episode of our 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt engages in an insightful, in-studio discussion with Dr. Anne Schuckman and Dr. Piyush Agarwal about contemporary strategies and challenges in the diagnosis of non-muscle invasive bladder cancer.

Could ctDNA testing allow us to treat bladder cancer earlier, smarter, and more effectively? In this episode of BackTable Urology, Dr. Alberto Pieretti, a urologic oncologist at Cleveland Clinic Weston Hospital, joins host Dr. Jose Silva to explore the emerging role of ctDNA in bladder cancer management.

How do you effectively treat your bladder cancer population with an insufficient supply of BCG? Dr. Amy Luckenbaugh, a urologic oncologist at Vanderbilt University Medical Center, joins host Dr. Ruchika Talwar to highlight challenges and solutions to managing bladder cancer amidst ongoing BCG shortages.

With BCG in short supply and recurrence rates still high, the race is on for better intravesical options. In this episode of BackTable Tumor Board, Dr. Lindsey Herrel, urologic oncologist at the University of Michigan, joins Dr. Ruchika Talwar to explore the evolving landscape of intravesical therapy for intermediate risk bladder cancer.

Counseling patients with intermediate-risk non-muscle invasive bladder cancer can be complex, with a wide range of treatment options and care pathways. In this episode of BackTable Urology, urologic oncologists Dr. Ruchika Talwar and Dr. Kelly Bree explore how to approach this challenge with clarity and compassion.

Do you need a recap of the latest urologic oncology research presented at GU ASCO 2025? This episode of BackTable Urology features a multidisciplinary discussion among three leading voices in urology and medical oncology – Drs. Bogdana Schmidt, Shilpa Gupta, and Ben Maughan – covering the most notable results presented at this year’s meeting.

Are you a private practice urologist looking to build your bladder cancer service lines? In this episode of the BackTable Urology Podcast, Dr. Tom Jayram, urologist from Nashville joins host Dr. Aditya Bagrodia to discuss the latest advancements in non-muscle invasive bladder cancer treatment. The conversation focuses on the unique experiences and practical considerations in managing this complex condition in the community setting.

Stay up to date in your bladder cancer practice with this insightful episode of the BackTable Urology podcast, developed in collaboration with the Society of Urologic Oncology. Dr. Betsy Koehne (University of Wisconsin) and Dr. Amir Salmasi (UC San Diego) talk through the contemporary management of low and intermediate-risk non-muscle-invasive bladder cancer.

Catch up on the latest breakthroughs in bladder cancer management. In this episode of the BackTable Urology Podcast, Dr. Bogdana Schmidt (University of Utah) speaks with Dr. Andrea Apolo, a medical oncologist at the National Cancer Institute, about recent advancements in bladder cancer treatment presented at the 2024 European Society of Medical Oncology (ESMO) Congress.

What is the role of blue light cystoscopy in bladder cancer? In this episode, Dr. Suzette Sutherland interviews Dr. Suzanne Merrill from Colorado Urology about the benefits of this technology in the diagnosis and treatment of bladder cancer, and how to implement it into your practice.

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros Grivas from Fred Hutchinson Cancer Center and Dr. Sumanta (Monty) Pal from City of Hope.

Dr. Ashish Kamat discusses contemporary management of high-risk, non-muscle-invasive bladder cancer (NMIBC) and his thoughts into the future of this arena.

In this episode of the BackTable Urology, Dr. Bogdana Schmidt (University of Utah), Dr. Woodson Smelser (Washington University in St. Louis), and Dr. Jeff Tosoian (Vanderbilt University) discusses the latest insights and advancements in prostate and bladder cancer treatment presented at AUA 2024.

This week on BackTable Urology, Dr. Suzette Sutherland (University of Washington) and Dr. Drew Peterson (Duke University) explore the psychological and clinical challenges faced by genitourinary cancer survivors dealing with the urological consequences of cystectomy and urinary diversion.

This week on BackTable Urology, Dr. Seth Lerner (Baylor College of Medicine) discusses the intricacies of lymph node dissection in bladder cancer management, including an overview of patterns of metastasis, genomic classifiers, and recent clinical trials.

In this special crossover episode with the Bladder Cancer Matters podcasts, Rick Bangs, a bladder cancer survivor, and Dr. Aditya Bagrodia, a urologic oncologist, discuss shared decision-making in bladder cancer treatment.

This week on BackTable Urology, urologic oncologist Dr. Bogdana Schmidt (University of Utah) hosts a discussion with medical oncology experts Dr. Rana McKay (UC San Diego) and Dr. Neeraj Agarwal (University of Utah) on recent clinical trials from bladder, kidney, and prostate cancer research presented at the 2023 European Society for Medical Oncology (ESMO) Meeting.

In this week’s BackTable Podcast, guests Dr. Sarah Psutka and Dr. Rachel Rubin join host Dr. Aditya Bagrodia to discuss the importance of considering women’s sexual health in urologic oncology surgeries.

In this episode of BackTable Urology, Dr. Aditya Bagrodia invites Dr. Yair Lotan, professor of urologic oncology at UT Southwestern, and oncologist Dr. Suzanne Cole to discuss types of adjuvant treatment for high risk bladder cancer, including chemotherapy, radiation therapy, and immunotherapy.

In this episode of BackTable Urology, Dr. Aditya Bagrodia speaks with two fellow urologic oncologists, Dr. Timothy Clinton (Brigham and Women’s Hospital) and Dr. Eugene Pietzak (Memorial Sloan Kettering), about the management of BCG-refractory non muscle-invasive bladder cancer.